Intellectual Property Protection In China Improving In Incremental Stages - BioBusiness 2009 Conference
This article was originally published in PharmAsia News
TAIPEI - China, generally thought to be a black hole for intellectual property, may be less dangerous for research-intensive pharmaceutical companies than is generally thought
You may also be interested in...
China's Supreme Court has given its final decision that upholds the original verdict of the 'Weige' trademark infringement case, rejecting Pfizer's appeal and putting an end to the company's 11-year trademark battle against Guangzhou Welman Pharmaceutical (PharmAsia News, April 14, 2008). According to Welman officials, China has an erectile dysfunction drug market worth tens of billions of renminbi but the combined revenue of the three-largest imported ED brands did not exceed RMB 100 million last year. The firm believes the non-standardized market has missed the best window of opportunity and will not be making a breakthrough in the short term. Welman evaluated the 'Weige' trademark to be worth some RMB 700 million ($102.5 million) and it does not discount collaborations with MNCs. (Click here for more - Chinese Language)
SHANGHAI - The Third Amendment of China's new Patent Laws passed by the 6th Session of the 11th Standing Committee of the National People's Congress on Dec. 27, means that the government can issue compulsory licenses on patented drugs in China, according to the new amendment
A regular roundup of commercial stories appearing in Scrip’s sister publication PharmAsia News, whose multilingual team of regional experts provides authoritative business intelligence focused on the Asian marketplace. Full stories can be accessed by clicking on the story title (subscription required).